Purdue-funded textbook scrapped at Toronto college; Lupin, Sunovion settle Lunesta patent fight;

@FiercePharma: GSK's Witty speaks small to think big. Report |  Follow @FiercePharma

> A complaint about perceived drug industry involvement in a pain management course for medical students has prompted the University of Toronto to revamp its curriculum. Story

> Lupin Pharmaceuticals settled its ongoing patent fight with Sunovion Pharmaceuticals over the sleep drug Lunesta with a deal that allows the generics maker to sell its version by November 2013. News

> Cephalon has tapped J. Kevin Buchi as CEO--a job he has been doing on an interim basis since August--after the recent death of company founder Frank Baldino. Report

> Mylan agreed to pay $65 million to settle a lawsuit by the U.S. and Texas alleging it inflated prescription drug prices, increasing the cost of reimbursing pharmacies and other providers. Item

> At least five workers were killed and eight others injured in an explosion at a Quanxin Pharmaceutical plant in southwest China's Yunnan province. Story

> Indian pharmaceutical companies led by Glenmark, Aurobindo and Sun Pharma maintained their No. 1 position in the U.S. generics market, by bagging 33 percent of 2010's generics approvals. Article

> India has rejected Abbott Laboratories' drug patent application for its combination HIV drug Kaletra. Report

> Sun Pharmaceutical Industries stock rose 1.36 percent after the company won tentative FDA approval for a generic version of Roche's Boniva. News

Biotech News

@FierceBiotech:  Burrill predicts big surge in biotech buyouts for 2011. News | Follow @FierceBiotech

> Genocea taps $35M venture round as it seeks new CEO. Item 

> Inspire shares tank after lead CF drug fails Phase III. Report

> Roche snaps up Marcadia Biotech. Story 

> 2010: Another blah year at FDA as new drug approvals slip. News 

> GSK's Witty looks to new blockbusters to reverse a bleak trend. Article

Biotech IT News

> RedOak readies natural-intelligence software for drug development. News 

> Jupiter trial results face calcium/cholesterol conundrum. Report 

> NCI trial-revamp plans call for IT overhaul. Story 

> EDC can aid in adverse event reporting. News 

> Poll: Pharma among industries needing more regulation. Article 

> FDA too rigid in review of drugs for critically ill. Item

And Finally... The Australian government is under fire for failing to maintain a register of gifts and benefits given to its Health Department officials by multibillion-dollar pharmaceutical companies. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.